<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite debates regarding its cardioprotection and pro-<z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, the definite mechanisms of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> on the heart are still unclear </plain></SENT>
<SENT sid="1" pm="."><plain>We determined the mechanistic effects of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> on cardiac function, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and <z:mpath ids='MPATH_124'>infarct</z:mpath> size during cardiac ischemic/reperfusion (I/R) </plain></SENT>
<SENT sid="2" pm="."><plain>Methods: Twenty-six rats were utilized </plain></SENT>
<SENT sid="3" pm="."><plain>In each rat, either <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> or saline solution was administered intravenously prior to a 30-minute left anterior descending coronary artery ligation and a 120-minute reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Cardiac function, <z:mpath ids='MPATH_124'>infarct</z:mpath> size, myocardial level of connexin43, Bax/Bcl-2, <z:chebi fb="1" ids="18070">cytochrome-c</z:chebi>, caspase-3, caspase-8, Akt, TNF-α, IL-4, and cardiac <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function were determined </plain></SENT>
<SENT sid="5" pm="."><plain>Isolated cardiomyocytes were used for studying intracellular calcium </plain></SENT>
<SENT sid="6" pm="."><plain>Results: <z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> did not alter cardiac function during the I/R periods, but increased the <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> score and mortality rate, decreased the time to <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo>, and prolonged <z:chebi fb="0" ids="29108">Ca2+</z:chebi> decay rate, compared to the saline group (P&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>However, the <z:mpath ids='MPATH_124'>infarct</z:mpath> size in the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group was decreased (P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> decreased the levels of connexin43 phosphorylation, active caspase-8, and TNF-α, but increased the procaspase-3 level </plain></SENT>
<SENT sid="9" pm="."><plain>However, levels of Bax/Bcl-2, <z:chebi fb="1" ids="18070">cytochrome-c</z:chebi>, Akt, IL-4, and cardiac <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function were not different between the two groups </plain></SENT>
<SENT sid="10" pm="."><plain>Conclusions: <z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> simultaneously exerted both beneficial and adverse cardiac effects in the I/R heart </plain></SENT>
<SENT sid="11" pm="."><plain>Although it decreased the <z:mpath ids='MPATH_124'>infarct</z:mpath> size via the extrinsic anti-apoptotic pathway, and anti-<z:mp ids='MP_0001845'>inflammation</z:mp>, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> facilitated a fatal <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> by decreasing the connexin43 phosphorylation, and prolonging the <z:chebi fb="0" ids="29108">Ca2+</z:chebi> decay rate in I/R rats </plain></SENT>
<SENT sid="12" pm="."><plain>The higher mortality rate in the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group suggests that its undesirable effect was more pronounced than its benefit on <z:mpath ids='MPATH_124'>infarct</z:mpath> size reduction </plain></SENT>
</text></document>